Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE LC versus MEDIHALER ERGOTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE LC versus MEDIHALER ERGOTAMINE.
HYDERGINE LC vs MEDIHALER ERGOTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist with additional affinity for 5-HT2, dopamine D2, and alpha-adrenergic receptors. It causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation.
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
One inhalation (0.36 mg ergotamine) at onset of migraine; may repeat after 5 minutes if needed, up to 6 inhalations per attack and 15 per week.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing.
The terminal elimination half-life is approximately 2 hours for the initial phase, followed by a prolonged terminal phase of 21-30 hours due to slow release from tissue binding sites. This long terminal half-life contributes to the risk of accumulation and toxicity with frequent dosing.
Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%).
Ergotamine is extensively metabolized in the liver. Approximately 90% of the dose is excreted as metabolites in the bile/feces, with less than 3% excreted unchanged in urine.
Category C
Category D/X
Ergot Alkaloid
Ergot Alkaloid